These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 30353605)

  • 41. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
    Vater I; Montesinos-Rongen M; Schlesner M; Haake A; Purschke F; Sprute R; Mettenmeyer N; Nazzal I; Nagel I; Gutwein J; Richter J; Buchhalter I; Russell RB; Wiestler OD; Eils R; Deckert M; Siebert R
    Leukemia; 2015 Mar; 29(3):677-85. PubMed ID: 25189415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Primary central nervous system lymphomas express Vh genes with intermediate to high somatic mutations.
    Sekita T; Tamaru JI; Kaito K; Katayama T; Kobayashi M; Mikata A
    Leuk Lymphoma; 2001 Apr; 41(3-4):377-85. PubMed ID: 11378551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary central nervous system lymphoma in Korea: comparison of B- and T-cell lymphomas.
    Choi JS; Nam DH; Ko YH; Seo JW; Choi YL; Suh YL; Ree HJ
    Am J Surg Pathol; 2003 Jul; 27(7):919-28. PubMed ID: 12826884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.
    Schmidt J; Federmann B; Schindler N; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
    Br J Haematol; 2015 Jun; 169(6):795-803. PubMed ID: 25819228
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW; Kim Y; Lee JH; Kim YS
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.
    Gonzalez-Aguilar A; Idbaih A; Boisselier B; Habbita N; Rossetto M; Laurenge A; Bruno A; Jouvet A; Polivka M; Adam C; Figarella-Branger D; Miquel C; Vital A; Ghesquières H; Gressin R; Delwail V; Taillandier L; Chinot O; Soubeyran P; Gyan E; Choquet S; Houillier C; Soussain C; Tanguy ML; Marie Y; Mokhtari K; Hoang-Xuan K
    Clin Cancer Res; 2012 Oct; 18(19):5203-11. PubMed ID: 22837180
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.
    Bruno A; Labreche K; Daniau M; Boisselier B; Gauchotte G; Royer-Perron L; Rahimian A; Lemoine F; de la Grange P; Guégan J; Bielle F; Polivka M; Adam C; Meyronet D; Figarella-Branger D; Villa C; Chrétien F; Eimer S; Davi F; Rousseau A; Houillier C; Soussain C; Mokhtari K; Hoang-Xuan K; Alentorn A
    Neuro Oncol; 2018 Jul; 20(8):1092-1100. PubMed ID: 29432597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma.
    Randen U; Trøen G; Tierens A; Steen C; Warsame A; Beiske K; Tjønnfjord GE; Berentsen S; Delabie J
    Haematologica; 2014 Mar; 99(3):497-504. PubMed ID: 24143001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.
    Fontanilles M; Marguet F; Bohers É; Viailly PJ; Dubois S; Bertrand P; Camus V; Mareschal S; Ruminy P; Maingonnat C; Lepretre S; Veresezan EL; Derrey S; Tilly H; Picquenot JM; Laquerrière A; Jardin F
    Oncotarget; 2017 Jul; 8(29):48157-48168. PubMed ID: 28636991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia.
    Kim JA; Im K; Park SN; Kwon J; Choi Q; Hwang SM; Sekiguchi N; Yoon SS; Lee DS; Kim SY
    Biomed Res Int; 2014; 2014():363540. PubMed ID: 24895570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.
    Tateishi K; Miyake Y; Kawazu M; Sasaki N; Nakamura T; Sasame J; Yoshii Y; Ueno T; Miyake A; Watanabe J; Matsushita Y; Shiba N; Udaka N; Ohki K; Fink AL; Tummala SS; Natsumeda M; Ikegaya N; Nishi M; Ohtake M; Miyazaki R; Suenaga J; Murata H; Aoki I; Miller JJ; Fujii Y; Ryo A; Yamanaka S; Mano H; Cahill DP; Wakimoto H; Chi AS; Batchelor TT; Nagane M; Ichimura K; Yamamoto T
    Cancer Res; 2020 Dec; 80(23):5330-5343. PubMed ID: 33067267
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
    Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma.
    Hattori K; Sakata-Yanagimoto M; Okoshi Y; Goshima Y; Yanagimoto S; Nakamoto-Matsubara R; Sato T; Noguchi M; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Chiba S
    Br J Haematol; 2017 May; 177(3):492-494. PubMed ID: 27161435
    [No Abstract]   [Full Text] [Related]  

  • 54. Highly sensitive
    Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
    Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.
    Montesinos-Rongen M; Godlewska E; Brunn A; Wiestler OD; Siebert R; Deckert M
    Acta Neuropathol; 2011 Dec; 122(6):791-2. PubMed ID: 22020631
    [No Abstract]   [Full Text] [Related]  

  • 56. Preneoplastic somatic mutations including
    Rodriguez S; Celay J; Goicoechea I; Jimenez C; Botta C; Garcia-Barchino MJ; Garces JJ; Larrayoz M; Santos S; Alignani D; Vilas-Zornoza A; Perez C; Garate S; Sarvide S; Lopez A; Reinhardt HC; Carrasco YR; Sanchez-Garcia I; Larrayoz MJ; Calasanz MJ; Panizo C; Prosper F; Lamo-Espinosa JM; Motta M; Tucci A; Sacco A; Gentile M; Duarte S; Vitoria H; Geraldes C; Paiva A; Puig N; Garcia-Sanz R; Roccaro AM; Fuerte G; San Miguel JF; Martinez-Climent JA; Paiva B
    Sci Adv; 2022 Jan; 8(3):eabl4644. PubMed ID: 35044826
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genomic Alterations and MYD88
    Jiang S; Qin Y; Gui L; Liu P; Jiang H; Liu B; Yang J; Yang S; He X; Zhou S; Du X; Yi Y; Lin J; Shi Y
    Target Oncol; 2020 Apr; 15(2):221-230. PubMed ID: 32239385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.
    Deckert M; Montesinos-Rongen M; Brunn A; Siebert R
    Acta Neuropathol; 2014 Feb; 127(2):175-88. PubMed ID: 24240734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma.
    Courts C; Montesinos-Rongen M; Brunn A; Bug S; Siemer D; Hans V; Blümcke I; Klapper W; Schaller C; Wiestler OD; Küppers R; Siebert R; Deckert M
    J Neuropathol Exp Neurol; 2008 Jul; 67(7):720-7. PubMed ID: 18596541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
    Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.